Table 1.

Baseline Characteristics of Enrolled Patients, by Group

Characteristic	Donor FMT (n = 22)	Autologous FMT (n = 24)
Mean age (SD), y	48 (16)	55 (14)
Female, n (%)	18 (82)	19 (79)
Mean body mass index (SD), kg/m2	28 (8)	27 (7)
Median Charlson Comorbidity Index score (range)	1 (0–4)	0 (0–3)
Mean duration of CDI since initial diagnosis (SD) [range], mo	9 (9) [3–36]	12 (12) [3–48]
Mean CDI recurrences (SD) [range], n	4 (2) [3–9]	5 (2) [2–10]
Mean duration of oral vancomycin therapy (SD) [range], wk*	28 (36) [6–140]	23 (30) [8–148]
Prior probiotic treatment, n (%)	15 (68)	18 (75)
Prior Lactobacillus GG use, n (%)	5 (23)	3 (13)
Prior Saccharomyces boulardii use, n (%)	11 (50)	13 (54)
Prior rifaximin use, n (%)	3 (13)	1 (4)
Prior fidaxomicin use, n (%)	6 (27)	8 (33)
Proton-pump inhibitor use, n (%)	2 (9)	2 (8)

CDI = Clostridium difficile infection; FMT = fecal microbiota transplantation.

^*For all prior CDI treatment courses combined; does not necessarily represent continuous use.